RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $425 from $417 and keeps an Outperform rating on the shares. The company reported its Q4 earnings, and the firm continues to see strong growth for Brukinsa with previously-feared competition leaving revs largely unimpacted, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $410 from $400 at Guggenheim
- BeOne Medicines price target raised to $405 from $394 at Barclays
- BeOne Medicines reports Q4 adjusted EPS $1.95, consensus $1.30
- BeOne Medicines sees 2026 revenue $6.2B-$6.4B, consensus $6.44B
- Beigene, Ltd. (ONC) Q4 Earnings Cheat Sheet